KR20090005369A - 중추 신경계 질환의 치료를 위한 (2ｓ)-(4ｅ)-ｎ-메틸-5-(3-이소프로폭시피리딘)일]-4-펜텐-2-아민의 다형체 제형 - Google Patents

중추 신경계 질환의 치료를 위한 (2ｓ)-(4ｅ)-ｎ-메틸-5-(3-이소프로폭시피리딘)일]-4-펜텐-2-아민의 다형체 제형 Download PDF

Info

Publication number
KR20090005369A
KR20090005369A KR1020087027218A KR20087027218A KR20090005369A KR 20090005369 A KR20090005369 A KR 20090005369A KR 1020087027218 A KR1020087027218 A KR 1020087027218A KR 20087027218 A KR20087027218 A KR 20087027218A KR 20090005369 A KR20090005369 A KR 20090005369A
Authority
KR
South Korea
Prior art keywords
polymorph
disease
amine
methyl
penten
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020087027218A
Other languages
English (en)
Korean (ko)
Inventor
게리 모리스 둘
줄리오 에이. 무노즈
Original Assignee
타가셉트 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 타가셉트 인코포레이티드 filed Critical 타가셉트 인코포레이티드
Publication of KR20090005369A publication Critical patent/KR20090005369A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
KR1020087027218A 2006-05-09 2007-05-08 중추 신경계 질환의 치료를 위한 (2ｓ)-(4ｅ)-ｎ-메틸-5-(3-이소프로폭시피리딘)일]-4-펜텐-2-아민의 다형체 제형 Abandoned KR20090005369A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74682106P 2006-05-09 2006-05-09
US60/746,821 2006-05-09

Publications (1)

Publication Number Publication Date
KR20090005369A true KR20090005369A (ko) 2009-01-13

Family

ID=38441430

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087027218A Abandoned KR20090005369A (ko) 2006-05-09 2007-05-08 중추 신경계 질환의 치료를 위한 (2ｓ)-(4ｅ)-ｎ-메틸-5-(3-이소프로폭시피리딘)일]-4-펜텐-2-아민의 다형체 제형

Country Status (29)

Country Link
US (3) US8461344B2 (https=)
EP (2) EP2418201B1 (https=)
JP (1) JP4477097B2 (https=)
KR (1) KR20090005369A (https=)
CN (1) CN101472893A (https=)
AR (1) AR060786A1 (https=)
AU (1) AU2007249485B2 (https=)
BR (1) BRPI0709781A2 (https=)
CA (1) CA2649961A1 (https=)
DK (1) DK2418201T3 (https=)
EC (1) ECSP088876A (https=)
ES (1) ES2460919T3 (https=)
HR (1) HRP20140385T1 (https=)
IL (1) IL194833A0 (https=)
MX (1) MX2008013982A (https=)
MY (1) MY144132A (https=)
NO (1) NO20084567L (https=)
NZ (1) NZ597177A (https=)
PL (1) PL2418201T3 (https=)
PT (1) PT2418201E (https=)
RS (1) RS53286B (https=)
RU (1) RU2440984C2 (https=)
SA (1) SA07280230B1 (https=)
SI (1) SI2418201T1 (https=)
TW (1) TWI389889B (https=)
UA (1) UA96447C2 (https=)
UY (1) UY30330A1 (https=)
WO (1) WO2007134034A1 (https=)
ZA (1) ZA200809284B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9049915B2 (en) 2010-04-23 2015-06-09 L'oreal Method for manufacturing a unit for applying a cosmetic product
KR101579904B1 (ko) 2014-09-05 2016-01-05 동신대학교산학협력단 마스카라

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790757B2 (en) 1998-06-16 2010-09-07 Targacept, Inc. Compounds capable of activating cholinergic receptors
UA88792C2 (ru) * 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
TWI389889B (zh) * 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
US8017785B2 (en) 2006-05-09 2011-09-13 Astrazeneca Ab Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
US20080085888A1 (en) * 2006-09-15 2008-04-10 Breining Scott R Therapeutic Combinations
WO2008091592A1 (en) * 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
KR20100052490A (ko) * 2007-07-31 2010-05-19 타가셉트 인코포레이티드 (2ｓ)-(4ｅ)-ｎ-메틸-5-(3-(5-이소프로폭시피리딘)일)-4-펜텐-2-아민의 경피투여
JP2011522886A (ja) * 2008-06-11 2011-08-04 アストラゼネカ・アクチエボラーグ （２ｓ）−（４ｅ）−ｎ−メチル−５−（３−（５−イソプロポキシピリジン）イル）−４−ペンテン−２−アミンを含む舌下組成物
WO2010080757A2 (en) * 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
US8703802B2 (en) * 2010-05-20 2014-04-22 Targacept, Inc. Process for the preparation of aryl substituted olefinic amines
WO2013184732A1 (en) * 2012-06-06 2013-12-12 Targacept, Inc. Crystalline (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]4-penten-2-amine 1,5-naphthalenedisulfonate

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4192946A (en) 1978-06-29 1980-03-11 Ciba-Geigy Corporation Process for producing 3-hydroxy-5-halopyridines
DE3148651A1 (de) 1981-12-09 1983-07-21 Henkel Kgaa "haarfaerbemittel, enthaltend 5-halo-2,3-pyridindiole als kupplerkomponente"
US4582823A (en) 1984-08-15 1986-04-15 Warner-Lambert Company Method for treating schizophrenia and medicaments therefor
WO1989000158A1 (en) 1987-07-02 1989-01-12 Pfizer Inc. Bridged-diazabicycloalkyl quinolone carboxylic acids and esters
IT1226727B (it) 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
DE69016688T2 (de) 1989-04-20 1995-10-05 Zambon Spa Dopamin-Medikament-Vorstufe.
US5187166A (en) 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
WO1992012122A1 (en) 1990-12-27 1992-07-23 Abbott Laboratories N-protected aminoalkylaldehydes
DE69213559T2 (de) 1991-05-30 1997-02-27 Mitsui Toatsu Chemicals Tetravinylpyrazine-Verbindung, Verfahren zur Herstellung derselben und elektrolumineszentes Element und damit hergesteller nichtlinearer optischer Stoff
US5212188A (en) 1992-03-02 1993-05-18 R. J. Reynolds Tabacco Company Method for treatment of neurodegenerative diseases
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
IT1274018B (it) 1994-02-23 1997-07-14 Riace Ets Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica
DK0765320T3 (da) 1994-06-14 2001-11-26 Pfizer Benzimidazolonderivater med central dopaminerg aktivitet
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US5616707A (en) 1995-01-06 1997-04-01 Crooks; Peter A. Compounds which are useful for prevention and treatment of central nervous system disorders
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US20020052497A1 (en) 2000-03-09 2002-05-02 Targacept, Inc. Compounds capable of activating cholinergic receptors
JP4357001B2 (ja) 1996-04-23 2009-11-04 ターガセプト，インコーポレイテッド 中枢神経系障害の予防及び治療のための医薬組成物
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US6979695B2 (en) 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
US5726189A (en) 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
US5811442A (en) 1997-02-21 1998-09-22 Bencherif; Merouane Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
PT983249E (pt) 1997-05-08 2002-08-30 Pfizer Prod Inc Procesos e intermediarios para a preparacao de derivados de indazole substituidos
ATE491689T1 (de) 1997-10-27 2011-01-15 Neurosearch As Heteroaryl diazacycloalkane als cholinergische ligande für nikotin-acetylcholin-rezeptoren
US6632823B1 (en) 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
US6232316B1 (en) 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
CA2677519A1 (en) 1998-06-16 1999-12-23 Targacept, Inc. Aryl substituted olefinic amines and their use as cholinergic receptors agonists
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
US6337351B1 (en) 1998-10-22 2002-01-08 Targacept, Inc. Pharmaceutical compositions and methods for use
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
FR2788982B1 (fr) 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
JP2003501416A (ja) 1999-06-07 2003-01-14 ターガセプト，インコーポレイテッド 医薬組成物およびその使用法
GB9922271D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Formulation
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
AU2001252350A1 (en) 2000-04-13 2001-10-30 Innovata Biomed Limited Medicaments for treating respiratory disorders comprising formoterol and fluticasone
US6743812B1 (en) 2000-07-14 2004-06-01 Targacept, Inc. Pharmaceutical compositions and methods for use
US6432954B1 (en) 2000-07-14 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
DE60222396T2 (de) 2001-03-29 2008-05-15 Eli Lilly And Co., Indianapolis N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste
GB2381750A (en) 2001-10-10 2003-05-14 Inspire Pharmaceuticals Inc Treatment for enhancing joint lubrication
EP1463481A4 (en) 2001-12-14 2008-06-25 Targacept Inc METHOD AND COMPOSITIONS FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM
AU2003226094A1 (en) 2002-03-27 2003-10-13 Smithkline Beecham Corporation Compounds and methods
US20040044023A1 (en) 2002-08-30 2004-03-04 Marc Cantillon Compositions and methods for treating or preventing memory impairment
US20050203130A1 (en) 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
WO2005063296A2 (en) 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders
US20050171088A1 (en) 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
WO2005105729A1 (en) 2004-02-13 2005-11-10 Mediquest Therapeutics, Inc. Polyamine analogs that activate antizyme frameshifting
US7537590B2 (en) 2004-07-30 2009-05-26 Microchips, Inc. Multi-reservoir device for transdermal drug delivery and sensing
JP4148199B2 (ja) 2004-07-30 2008-09-10 松下電工株式会社 電気かみそり
JP5254616B2 (ja) 2004-09-13 2013-08-07 クロノ セラピューティクス、インコーポレイテッド 生物学的同調性（ｂｉｏｓｙｎｃｈｒｏｎｏｕｓ）経皮的薬物送達
UA88792C2 (ru) * 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
US7459469B2 (en) * 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
US8017785B2 (en) 2006-05-09 2011-09-13 Astrazeneca Ab Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
US20080138416A1 (en) 2006-06-13 2008-06-12 Fmc Biopolymer As Method and systems for using biopolymer-based beads and hydrogels
US20080085888A1 (en) 2006-09-15 2008-04-10 Breining Scott R Therapeutic Combinations
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
WO2008091592A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9049915B2 (en) 2010-04-23 2015-06-09 L'oreal Method for manufacturing a unit for applying a cosmetic product
US9700118B2 (en) 2010-04-23 2017-07-11 L'oreal Unit for application of a cosmetic product
KR101579904B1 (ko) 2014-09-05 2016-01-05 동신대학교산학협력단 마스카라

Also Published As

Publication number Publication date
HRP20140385T1 (hr) 2014-06-06
IL194833A0 (en) 2009-08-03
SI2418201T1 (sl) 2014-06-30
US8461344B2 (en) 2013-06-11
BRPI0709781A2 (pt) 2011-07-26
JP4477097B2 (ja) 2010-06-09
AU2007249485B2 (en) 2012-11-01
TW200808726A (en) 2008-02-16
CA2649961A1 (en) 2007-11-22
MY144132A (en) 2011-08-15
NZ597177A (en) 2013-06-28
EP2021326A1 (en) 2009-02-11
US20130310425A1 (en) 2013-11-21
MX2008013982A (es) 2009-03-13
WO2007134034A1 (en) 2007-11-22
PT2418201E (pt) 2014-04-14
US20070265314A1 (en) 2007-11-15
ZA200809284B (en) 2009-08-26
ES2460919T3 (es) 2014-05-16
JP2009531465A (ja) 2009-09-03
AU2007249485A1 (en) 2007-11-22
UA96447C2 (ru) 2011-11-10
RU2008148325A (ru) 2010-06-20
RS53286B (sr) 2014-08-29
NO20084567L (no) 2008-12-04
US20100048643A1 (en) 2010-02-25
PL2418201T3 (pl) 2014-07-31
RU2440984C2 (ru) 2012-01-27
UY30330A1 (es) 2008-10-31
CN101472893A (zh) 2009-07-01
SA07280230B1 (ar) 2010-08-20
EP2418201B1 (en) 2014-02-12
TWI389889B (zh) 2013-03-21
DK2418201T3 (da) 2014-05-12
AR060786A1 (es) 2008-07-10
EP2418201A1 (en) 2012-02-15
ECSP088876A (es) 2009-02-27

Similar Documents

Publication Publication Date Title
AU2007249485B2 (en) Polymorph forms of (2S) - (4E) -N-methyl-5- (3-isopropoxypyridin) yl] -4-penten-2-amine for the treatment of central nervous system disorders
EP1814852B1 (en) Hydroxybenzoate salts of metanicotine compounds
AU2018251119B2 (en) Opioid receptor (MOR) agonist salt, fumarate salt I crystal form thereof and preparation method thereof
JP2026031970A (ja) Ｇｌｐ－１受容体アゴニストの結晶形ａおよびその調製法
JP5405311B2 (ja) ｍＧｌｕＲ５受容体アンタゴニストの多形
US8017785B2 (en) Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
CA2657541A1 (en) Pharmaceutically acceptable salt and polymorphic forms of flupirtine maleate
CN110023310A (zh) 用于调节激酶级联的联芳组合物和方法
EP4635952A1 (en) Solid form of n-substituted phenylsulfonamide compound
US9149468B2 (en) Multicomponent crystals made ([2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-carbamic acid ethyl ester and 2-[2-[(2,6-dichlorphenyl)-amino]-phenyl]-acetic acid
WO2019076904A1 (en) PROPANAMINE DERIVATIVES FOR THE TREATMENT OF PAIN AND PAIN DISEASES ASSOCIATED WITH PAIN
EP2206700A1 (en) Crystalline form of flupirtine ((2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl)-carbamic acid ethyl ester)
WO2013184732A1 (en) Crystalline (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]4-penten-2-amine 1,5-naphthalenedisulfonate
EP2206701A1 (en) Crystalline form of flupirtine ((2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl)-carbamic acid ethyl ester)
PT2300473E (pt) Sal de fumarato de 1,4-diazabiciclo[3.2.2]nonano-4-carboxilato de 4-bromofenilo, suas formas cristalinas, sua preparação e sua utilização em terapia
NZ616076A (en) Derivatives of sulindac, use thereof and preparation thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20081106

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120503

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130820

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140227

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20140821

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee